Synonyms: GSK-1521498
Compound class:
Synthetic organic
Comment: GSK1521498 is a μ opioid receptor antagonist [4-5] in clinical development for disorders of compulsive consumption (e.g stimulant drug seeking, binge eating [7], or excessive alcohol consumption). It is >10-fold selective for human μ receptor compared to the κ and δ receptors in vitro [4]. It may be used experimentally as the phosphate with IUPAC name N-{[3,5-difluoro-3′-(1H-1,2,4-triazol-3-yl)-4-biphenylyl]methyl}-2,3-dihydro-1H-inden-2-amine phosphate (1:1). The chemical structure of GSK1521498 is claimed in patent US8822518 [2], with prior chemical series claimed in WO2008021849 [1].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
In vitro, GSK1521498 behaves as an inverse agonist when the μ opioid receptor is overexpressed, but behaves as an antagonist at low receptor levels [5]. Safety and PK/PD of GSK1521498 in healthy subjects is published in [6]. |
Selectivity at GPCRs | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|